Digg It - Finance

Chapter 13 bankruptcy is for individuals in the United States who would like to under

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

go a financial reconstruction supervised by a federal bankruptcy court. This chapter

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

allows income receiving debtors a debtor rehabilitation, provided they fulfill a cour

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

-approved plan. Chapter 7 governs the process of liquidation under the bankruptcy la

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

s of the United States. A Chapter 7 filing means that the business intends to sell a

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

l its assets, distribute the proceeds to its creditors and cease all operations. If t

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

e debtor lacks sufficient disposable income, then it is viable to fund a Chapter 13 p

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

lan.

In a Chapter 13 reconstruction, the debtor proposes to pay his creditors over a

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

3-5 year period. Under Chapter 7 filing, creditors with secured loans are given fir

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

t preference over the debtor?s assets. Under Chapter 13, the debtor?s creditors cann

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

t attempt to collect on the individual?s previous incurred debt during the rehabilita

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

ion period except through the bankruptcy court.

In this case, they end up with less

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

oney than they are owed.

In a Chapter 7 case availability of future credit is diffic

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

ilt to ascertain and, in some cases, not possible.

However, in a Chapter 13 case, cr

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

edit can be permitted upon obtaining the Chapter 13 trustee?s permission. In both t

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

e chapters the disadvantage of filing for bankruptcy is that a record of it stays on

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

the individual?s credit report for 10 years. The advantage of filing under Chapter 1

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

is the abiity to stop foreclosures and to have accelerated mortgages reinstated upon

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

the completion of the bankruptcy plan. The advantage of filing under

Chapter 7 is th

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

t the debtor is allowed certain exemptions like child support, retirement income, etc

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggit.org.ua/article/90914/diggit-Chapter-7-vs-Chapter-13-Bankruptcy.html">Chapter 7 vs. Chapter 13 Bankruptcy</a>

BB link (for phorums):
[url=http://www.diggit.org.ua/article/90914/diggit-Chapter-7-vs-Chapter-13-Bankruptcy.html]Chapter 7 vs. Chapter 13 Bankruptcy[/url]

As your firm enters 2007, do you have this problem and other major business decisions? How can I grow or sustain my firm? How can I attract new clients and customers? Frequent recognition of your business through press releases can be the answer...

I think another big barrier to success online is the tendency to jump on every new bandwagon that comes along, to join every new program that comes along. I can tell you this, there is not get rich quick scheme online that will really get you rich quick.

Cooperative Marketing sets a new paradigm in MLM Marketing! See how a chosen few insiders are capitalizing off of a little known technique that creates residual income in their MLM Programs without requiring them to sell, recruit or spend a nickel on advertising without knowing exactly what to expect in return.

Tags

Links

Digg It - Chapter 7 vs. Chapter 13 Bankruptcy

Related Articles: